Clinical Trials Sponsored by Kadmon Pharmaceuticals

Total 19771 results

Kadmon Corporation, LLC

Completed

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

Psoriasis Vulgaris

United States
Kadmon Corporation, LLC

Terminated

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

HER-2 Positive Breast Cancer | Metastatic Malignant Neoplasm to Brain

United States
Kadmon Corporation, LLC

Completed

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Kadmon Corporation, LLC

Completed

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States
Kadmon Corporation, LLC

Completed

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Glioblastoma | Brain Tumor | Recurrent Glioblastoma

United States
Kadmon Corporation, LLC

Completed

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Kadmon Corporation, LLC

Completed

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Completed

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Polycystic Kidney, Autosomal Recessive

United States
Kadmon Corporation, LLC

Completed

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Non-Small Cell Lung Cancer | Brain Metastases | Leptomeningeal Metastases

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Carcinoma, Non-Small-Cell Lung

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Non-small-cell Lung Cancer

United States
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
Kadmon Corporation, LLC

Withdrawn

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C (REACHSVR)

Hepatitis C
Kadmon Corporation, LLC

Terminated

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (ENHANCE)

Hepatitis C

United States
Jiangsu Kanion Pharmaceutical Co., Ltd

Not yet recruiting

A Prospective Cohort Study of Compound Nanxing Zhitong Ointment

Chronic Musculoskeletal Pain
Jiangsu Kanion Pharmaceutical Co., Ltd

Completed

Effect of KYG0395 on Primary Dysmenorrhea

Primary Dysmenorrhea

United States
Jiangsu Kanion Pharmaceutical Co., Ltd

Completed

A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam

Pharmacokinetics

China
Kadmon, a Sanofi Company

Recruiting

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Chronic Graft Versus Host Disease

United States
Kadmon, a Sanofi Company

Terminated

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | System; Sclerosis

United States
Kadmon, a Sanofi Company

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Graft vs Host Disease

United States
Kadmon, a Sanofi Company

Terminated

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

United States
Kadmon, a Sanofi Company

Terminated

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Chronic Graft-versus-host-disease

United States
Kadmon, a Sanofi Company

Completed

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Immune System Disorder (Healthy Volunteers)

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Completed

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Kadmon Corporation, LLC
Quotient Sciences

Completed

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 (KD025-108)

Fibrosis | Autoimmune Diseases

United Kingdom
Kadmon Corporation, LLC
Quotient Clinical

Completed

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Bioavailability

United Kingdom
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
Kadmon, a Sanofi Company

Active, not recruiting

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Chronic Graft-versus-host-disease

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Terminated

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSC)

Diffuse Cutaneous Systemic Sclerosis

United States
Kadmon, a Sanofi Company

Completed

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

United States
Kadmon, a Sanofi Company

Completed

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Kadmon Corporation, LLC
Quotient Sciences

Completed

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Autoimmune Diseases | Drug-drug Interaction | Fibrotic Disease

United Kingdom
Suzhou Raymon Pharmaceuticals Company, Ltd.
WuXi Clinical

Active, not recruiting

RMP-A03 Ocular Suspension in Patients With Pterygium

Pterygium

United States
RenJi Hospital
Jiangsu Kanion Pharmaceutical Co., Ltd

Unknown

Ginkgo Diterpene Lactone Meglumine Injection on Platelet Reactivity in Acute Ischemic Stroke (GDPRS)

Ischemic Stroke
Shanghai Mental Health Center
Jiangsu Kanion Pharmaceutical Co.

Unknown

Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers

PHA1A

China
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Jiangsu Kanion Pharmaceutical Co., Ltd
Shanghai Mental Health Center

Not yet recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia (TPN672)

Schizophrenia

China
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States

3

Subscribe